Experts have recommended that, for patients with cancer-related pain who are using nonmedical stimulants, opioids should be continued, monitoring should be increased, and tapering should be avoided.
Pharmaceutical experts review ocular adverse effects related to antibody-drug conjugates.
Ocular side effects of immune checkpoint inhibitors are considered rare but may be underreported.
During end-of-life care, cancer patients who utilized spiritual, psychology, and social work services received different oncologic treatment.
Major advances in cancer treatment in recent decades have allowed patient survival rates to increase.
Heron Therapeutics announced that the Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Cinvanti (aprepitant) to expand administration to include a 2-minute intravenous (IV) injection, in addition to the already approved 30-minute IV infusion.
CINV and RINV are a frequent source of misery and distress for patients and ineffective emesis control has well-documented impacts on health-related quality of life.
Patients who receive chemotherapy or radiation therapy are at risk for developing oral mucositis, which causes inflammatory and/or ulcerative lesions of the oral mucosa
Researchers noted that while non-drug costs account for only 7% of CAR-T therapy-related expenses, these costs may range from $30,000 to $56,000.
Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.
Please login or register first to view this content.
